+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Stelara

  • ID: 4775305
  • Report
  • August 2018
  • Region: Global
  • 57 pages
  • Datamonitor Healthcare
1 of 2

Enquire about COVID-19 updates for this product.

Enquire Now
Drug Overview
Stelara (ustekinumab; Johnson & Johnson/Mitsubishi Tanabe) is a high-affinity, fully human monoclonal antibody that targets the p40 subunit of cytokines interleukin (IL)-12 and IL-23 proteins that occur in the immune system.

Stelara is currently approved for the treatment of psoriasis, psoriatic arthritis, and Crohn’s disease, and is undergoing Phase III trials in ulcerative colitis.
Note: Product cover images may vary from those shown
2 of 2
OVERVIEW
Drug Overview
Product Profiles
Stelara: Crohn's disease
Stelara: Psoriatic arthritis
Stelara: Ulcerative colitis
Stelara: Psoriasis

LIST OF FIGURES
Figure 5: Filgotinib for Crohn’s disease – SWOT analysis
Figure 4: Filgotinib for Crohn’s disease – SWOT analysis
Figure 21: The authors drug assessment summary of Stelara in Crohn’s disease
Figure 11: The authors drug assessment summary of Cimzia in Crohn’s disease
Figure 25: The authors drug assessment summary of Tysabri in Crohn’s disease
Figure 6: Ozanimod sales for Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016–25
Figure 28: The authors drug assessment summary of ozanimod in Crohn’s disease
Figure 15: Upadacitinib for Crohn’s disease – SWOT analysis

LIST OF TABLES
Table 1: Stelara drug profile
Table 2: Stelara sales for Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016–25
Table 3: Stelara drug profile
Table 4: Stelara pivotal trial data in psoriatic arthritis
Table 5: Stelara drug profile
Table 6: Stelara drug profile
Table 7: Stelara pivotal trial data in adult psoriasis
Table 8: Stelara pivotal trial data in adolescent psoriasis
Table 9: Stelara late-phase trial data in psoriasis
Table 10: Cumulative rates of adjudicated major adverse cardiovascular events in five-year follow-up study on Stelara
patients
Table 11: Treatment-emergent infections in patients treated with Stelara through up to five-year follow-up
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll